Quiet on the insider front: nobody at Context Therapeutics Inc. bought or sold CNTX shares in open-market trades this past year.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. Big money check: 79 institutions held CNTX as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Lehr Martin A. | CEO | Buy | 100,000 | $0.70 | $70K | SEC |
| Jun 10, 2025 | Levit Alex C. | Executive Officer | Buy | 20,000 | $0.58 | $12K | SEC |
| Jun 10, 2025 | Minai-Azary Jennifer Lynn | CFO | Buy | 40,010 | $0.64 | $26K | SEC |
| Feb 21, 2023 | Lehr Martin A. | CEO | Buy | 5,823 | $0.84 | $5K | SEC |
| Feb 13, 2023 | Lehr Martin A. | CEO | Buy | 5,606 | $0.87 | $5K | SEC |
| Feb 6, 2023 | Lehr Martin A. | CEO | Buy | 5,040 | $0.97 | $5K | SEC |
| Jan 30, 2023 | Lehr Martin A. | CEO | Buy | 7,027 | $0.70 | $5K | SEC |
| Jan 23, 2023 | Lehr Martin A. | CEO | Buy | 6,839 | $0.72 | $5K | SEC |
| Jan 18, 2023 | Lehr Martin A. | CEO | Buy | 6,783 | $0.74 | $5K | SEC |
There were no open-market insider trades in CNTX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
79 investment managers reported holding CNTX in SEC Form 13F filings for Q2 2026.
No congressional trades in CNTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).